Lutikizumab

Highest phase reached
Phase 3
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 3
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Lutikizumab
www.ebi.ac.uk

  • a 1234138
  • A-1234138
  • abt 981
  • Abt-981
  • ABT-981
  • immunoglobulin anti interleukin 1β interleukin 1α synthetic human a 1234138 heavy chain disulfide with synthetic human a 1234138 light chain dimer
  • immunoglobulin g1 kappa anti homo sapiens il1a interleukin 1 alpha and homo sapiens il1b interleukin 1 beta il 1b 1l1f2 humanized monoclonal antibody tetravalent bispecific gamma1 heavy chain 1 577 humanized vh anti il1b homo sapiens ighv3 23 04 80 60 ighd ighj4 01 8 8 12 1 119 6 mer linker 120 125 homo sapiens vh anti il1a ighv3 30 03 88 80 ighd ighj1 01 8 8 15 126 247 homo sapiens ighg1 01 ch1 248 345 hinge 346 360 ch2 l1 3 a 364 l1 2 a 365 361 470 ch3 471 575 chs 576 577 248 577 350 327 disulfide with kappa light chain 1 327 humanized v kappa anti il1b homo sapiens igkv1 27 01 82 10 igkj2 01 6 3 9 1 106 7 mer linker homo sapiens v kappa anti il1a igkv1 12 01 92 60 igkj4 01 6 3 9 114 220 homo sapiens igkc 01 km3 221 327 dimer 356 356 359 359 bisdisulfide
  • Immunoglobulin G1-kappa, anti-[Homo sapiens IL1A (interleukin 1 alpha) and Homo sapiens IL1B (interleukin 1 beta, IL-1B, 1L1F2)], humanized monoclonal antibody, tetravalent bispecific; gamma1 heavy chain (1-577) [humanized VH anti-IL1B (Homo sapiens IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125)-Homo sapiens VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -Homo sapiens IGHG1*01 (CH1 (248- 345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1’-327’) [humanized V-KAPPA anti-IL1B (Homo sapiens IGKV1- 27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker-Homo sapiens V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220')-Homo sapiens IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide
  • Immunoglobulin, anti-(interleukin 1β/interleukin 1α) (synthetic human A-1234138 heavy chain), disulfide with synthetic human A-1234138 light chain, dimer
  • lutikizumab
  • Lutikizumab
  • lutikizumab [INN]
  • LUTIKIZUMAB [USAN]
  • Lutikizumab [WHO-DD]
  • lutikizumab inn
  • lutikizumab usan
  • lutikizumab who dd

CAS registry numbers
  • 1791411-57-8
ChEMBL ID
CHEMBL4594518
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • 15FAZ725S0

First in class
No
Orphan designation
No

Pharmacology name
lutikizumab
Type
Antibody
Drug name stem
-mab; -mab

  • Action
    Binding
    Action type
    Binding
    Target
    IL-1α
    Gene symbol
    IL-1α
    Median affinity
    11.12
    Affinity units
    pKd
    Primary target
    Yes
  • Action
    Binding
    Action type
    Binding
    Target
    IL-1β
    Gene symbol
    IL-1β
    Median affinity
    10.68
    Affinity units
    pKd
    Primary target
    Yes
  • Mechanism
    Interleukin-1 alpha inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-1 alpha
    Protein identifier
    P01583
  • Mechanism
    Interleukin-1 beta inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-1 beta
    Protein identifier
    P01584

  • Mechanism
    Interleukin-1 alpha inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-1 alpha
  • Mechanism
    Interleukin-1 beta inhibitor
    Action type
    Inhibitor
    Target
    Interleukin-1 beta

  • Condition
    Colitis, Ulcerative
    Highest recorded phase
    2
    Condition identifier
    EFO:0000729
    Subject identifier
    D003093
  • Condition
    Osteoarthritis, Knee
    Highest recorded phase
    2
    Condition identifier
    EFO:0004616
    Subject identifier
    D020370
  • Condition
    Hidradenitis Suppurativa
    Highest recorded phase
    3
    Condition identifier
    EFO:1000710
    Subject identifier
    D017497
  • Condition
    Osteoarthritis
    Highest recorded phase
    1
    Condition identifier
    MONDO:0005178
    Subject identifier
    D010003

  • Condition identifier
    EFO_0000274
    Highest recorded phase
    2
  • Condition identifier
    EFO_0000729
    Highest recorded phase
    2
  • Condition identifier
    EFO_0004616
    Highest recorded phase
    2
  • Condition identifier
    EFO_1000710
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0002400
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0004980
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005011
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005101
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005178
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0005416
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0006559
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0008383
    Highest recorded phase
    2
  • Condition identifier
    MONDO_0011849
    Highest recorded phase
    2

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Glycosylation sites (N)
    Sequence
    427 $ 427''''
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLQESGPGLVKPSETLSLTCAVTGYSITSGYSWHWIRQFPGNGLEWMGYIHSSGSTNYNPSLKSRISISRDTSKNQFFLKLSSVTAADTAVYYCAGYDDYFEYWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Glycosylation sites (N)
    Sequence
    427 $ 427''
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCKASQNVGFNVAWYQQKPGKSPKALIYSASYRYSGVPSRFSGSGSGTDFTLTISSLQPEDFAEYFCQQYNWYPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVESGGGVVQPGRSLRLSCSASGFIFSRYDMSWVRQAPGKGLEWVAYISHGGAGTYYPDSVKGRFTISRDNSKNTLFLQMDSLRPEDTGVYFCARGGVTKGYFDVWGQGTPVTVSSASTKGPQVQLVESGGGVVQPGRSLRLSCTASGFTFSMFGVHWVRQAPGKGLEWVAAVSYDGSNKYYAESVKGRFTISRDNSKNILFLQMDSLRLEDTAVYYCARGRPKVVIPAPLAHWGQGTLVTFSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 136'-201' $ 136'''-201''' $ 147-221 $ 147''-221'' $ 247-307' $ 247''-307''' $ 274-330'' $ 274-330'' $ 350-327' $ 350''-327'' $ 356-356'' $ 359''-359'' $ 391-451 $ 391''-451'' $ 359''-359'' $ 497-555 $ 497''-555''
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 143-199 $ 143''-199'' $ 219-214' $ 219''-214''' $ 225-225'' $ 228-228'' $ 260-320 $ 260''-320'' $ 366-424 $ 366''-424''

Related records

Trials (12)

In development for (5)

Targets (2)